Royalty Pharma plc
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $17.9M | $294.7M | $288.2M | $32.2M | $239.3M | $544.0M | $102.0M | $4.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | $1.2M | — | — | $0 | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $122.0M | — | — | $515.0K | — | — | $612.0K |
| Net Cash from Operating Activities | $728.5M | $718.2M | $702.6M | $364.0M | $596.1M | $703.6M | $658.2M | $664.6M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-477.9M | — | — | $503.9M | — | — | $-86.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | $50.1M | — | — | $708.8M | — | — | $0 |
| Net Cash from Financing Activities | — | $-272.7M | — | — | $-941.3M | — | — | $-212.0M |
| Net Change in Cash | — | $-32.3M | — | — | $158.7M | — | — | $366.0M |
| Free Cash Flow | — | — | — | — | — | — | — | — |